Ophthotech ( NASDAQ : OPTH ) got crushed 85 % in today's trade , after it announced that its key drug Fovista failed in phase 3 trials on wet AMD ...
... the stock plummeted from $US 39 , down to $US 5 + change ...
Market Cap smashed from $US 1500 million , to $US 200 m. : Ouch !
... next cab off the rank , step right up to stage : Opthea !
Well , I guess the failure of Fovista puts more of a spotlight on our product ...
... a lesson for wannabe investors : Bio-techs are not for the faint hearted ..
really really good, page-5
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
65.5¢ |
Change
-0.045(6.43%) |
Mkt cap ! $855.6M | |||
| Open | High | Low | Value | Volume |
| 69.5¢ | 69.5¢ | 63.0¢ | $2.808M | 4.305M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 49996 | 65.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 66.0¢ | 50869 | 6 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| OPT (ASX) Chart |
